An Expert Overview of Eye Issues From Antibody Drug Conjugates

Video

Antibody drug conjugates, which are used to treat various types of cancer, can cause eye issues, though they are easily treated if caught early, one expert said.

While antibody drug conjugates typically have fewer side effects than standard chemotherapy, they can cause ocular (eye-related) toxicities that, if experienced by patients, should be discussed with the health care team, according to Dr. Meghan K. Berkenstock, an associate professor of Ophthalmology at Johns Hopkins Medicine in Baltimore.

According to the National Cancer Institute, antibody drug conjugates work by targeting proteins found on cancer cells. Once they find and latch onto that protein, they deliver cancer-fighting drugs to kill the cell. This method typically spares many healthy cells, though the targeted protein can be found on some healthy cells such as those found in the eyes as well.

MORE: Antibody Drug Conjugates ‘Make Chemotherapy Targeted’ for Patients With Cancer

As a result, patients taking antibody drug conjugates to treat their cancer may experience redness, irritation, blurriness or other eye-related side effects, Berkenstock explained. These issues should be brought up to the health care team right away, according to Berkenstock, as they can be easily treated when caught early.

Transcription

So the medications are specifically targeted to proteins on the cell surface that are increased in the cancer cells. Unfortunately, there are cells in our bodies that are not cancer cells that also have these receptors, and that's what the problem with the eye and other associated structures around the eye occur.

Because the targeted molecules go into those cells that cause the cells to die, and it causes the outer layers of the eye, the conjunctiva, and also the cornea to have a pitted surface or an irritated surface — and that's what leads to your development of your red eyes, your irritation, your blurriness, the crusting and, certainly, the drop in the vision.

Whenever those things happen, you have to tell your provider because dose adjustments or delays in the medication administration can happen; it doesn't mean we have to stop your treatment. Because if we can catch these diseases early in their time course, they're easily treated, and very rarely do we have something that would stop or impact when the medication can be given. And so being forthwith, following up with ophthalmology at baseline, and also going to your (eye) exams, even when you're busy with other doctors, and certainly taking other medications and adding drops to your current regimen (can help). And it's another expense, but it really preserves and prevents the eyes from having any untoward side effects. And that's why we have to deal with the side effects, but again, completely manageable, and allows you to get your treatment the way you're supposed to.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Image of a woman with brown shoulder-length hair in front of a gray background that says CURE.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Related Content